A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Clinical trial NCT05495464 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05495464
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-18
- Primary completion
- 2027-03-31
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.